Fortress Biotech, Inc.
For the period ended Jan 13, 2026. Filed Jan 13, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Jan 13, 2026 · Filed Jan 13, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Renal Dysfunction
Renal Dysfunction
Kidney injury has been reported in patients taking ZYCUBO. In patients with Menkes disease, kidney dysfunction may already be present from the accumulation of copper in the kidneys. This may be worsened from the administration of copper in ZYCUBO. The healthcare team will monitor your child's kidney function through periodic laboratory tests before and during ZYCUBO administration. The dose of ZYCUBO may be adjusted as appropriate based on the results of the laboratory tests.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.